Citius Oncology, Inc. (CTOR)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$0.8735−8.05%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $92.4M
- 52-week range
- $0.491 – $2.25
- 52-week change
- −49.20%
- EPS (trailing)
- −$0.48
Fiscal year to Sep 2025
- Net income
- −$24.8M
- Diluted EPS
- −$0.34
From the company’s annual report on SEC EDGAR.
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Headquarters: Cranford, United States · citiusonc.com/overview/default.aspx